LCI 1Alternative Names: LCI-1
Latest Information Update: 08 Dec 2009
At a glance
- Originator Eli Lilly
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 19 Nov 2009 Clinical trials in Cancer in USA (unspecified route)